Placeholder Banner

Biotech Leaders Hit the Airwaves to Talk About Industry’s Efforts to Eradicate Covid-19

Andrew Segerman
April 1, 2020

As the novel coronavirus continues to spread, scientists and researchers are working around the clock to identify diagnostics, therapeutics and vaccines to help protect individuals and communities across the globe. This week, leaders within the biopharmaceutical industry took to the airwaves, joining radio shows across the country to assure the American people that help is on the way. 

BIO’s CEO Jim Greenwood spoke on WDUN’s The Martha Zoller Show in Atlanta about what the industry is doing to beat the coronavirus. Biopharmaceutical innovators have “pulled together” to share “information and resources” in an effort to get medicines and vaccines to people as quickly as possible, he explained. 

Greenwood also joined WWDB-AM Philadelphia where he highlighted the researchers and scientists who are working around the clock to save lives. “We’re not thinking about money, we’re not thinking about commercial opportunities,” he noted.

Echoing Greenwood’s comments, Dr. Jeremy Levin, CEO of Ovid Therapeutics and BIO’s chair, told Nikki Medoro on KGO 810 in San Francisco that “the industry is pulling together right now.” On The Ross Kaminsky Show serving the Denver area, Dr. Levin added that “we have the tools to tackle” Covid-19 and we’ve learned many lessons from previous fights like those against SARS and MERS. “We are on the road, that’s for sure,” Dr. Levin told Kaminsky in a separate conversation when asked how long it would be until we have safe, proven products available for patients. 

In a conversation with The Glenn Woods Show in Wyoming, Rich Masters, BIO’s Executive Vice President for Public Affairs, explained that “we need three things” to stop the spread of this deadly pathogen: new diagnostics, therapeutics and vaccines. “One of the best things about America is the resilience we have and our private companies are stepping up to help the government get to a solution.” 

To learn more about how the biopharmaceutical industry is responding to Covid-19, click here.